Premium
The treatment of patients with chronic mucocutaneous candidosis and Candida onychomycosis with ketoconazole
Author(s) -
HAY R.J.,
CLAYTON Y.M.
Publication year - 1982
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.1982.tb02403.x
Subject(s) - ketoconazole , medicine , dermatology , mucocutaneous zone , chronic mucocutaneous candidiasis , antifungal , pathology , disease
Summary Twenty patients with chronic mucocutaneous candidosis (CMCC) and eleven patients with Candida onychomycosis (CO) were treated with oral ketoconazole. Twenty‐seven patients completed therapy after a mean treatment duration of 7‐6 months and were both clinically and mycologically free from infection. Clinical and mycological relapse was seen in five CMCC and one CO patient during follow up post treatment (8‐4 months mean). All the patients with CMCC who relapsed after ketoconazole presented with recurrent oral candidosis. During treatment, side effects such as nausea, headache and dizziness were seen in seven patients. The mean blood level of the drug i h after 200 mg of ketoconazole was 2–2 mg/1, although some patients showed persistently low levels, below 0‐4 mg/1. The use of ketoconazole is a significant advance in the management of chronic Candida infections of the nails. The relapse rate is low and there is a prompt response to retreatment.